Literature DB >> 6779565

Deep venous thrombosis: predictive value of signs and symptoms.

H S Vine, B Hillman, S J Hessel.   

Abstract

The clinical history, signs, symptoms, and laboratory and radiographic results of 154 consecutive patients who had contrast phlebography for evaluation of deep venous thrombosis were evaluated retrospectively to determine their relationship to deep venous thrombosis. Malignancy, history of recent blood transfusions, recent surgery, congestive heart failure, immobility, and infection exhibited the strongest correlation with acute thrombophlebitis. Receiver operating characteristic curves were constructed to demonstrate the additive value of certain signs and symptoms in predicting the development of or protection from deep venous thrombosis. With these curves, a cutoff point can be selected for this population that will aid in determining which patients should undergo further diagnosis and/or treatment in the evaluation of deep venous thrombosis.

Entities:  

Mesh:

Year:  1981        PMID: 6779565     DOI: 10.2214/ajr.136.1.167

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Acquired deep venous thrombosis in children.

Authors:  A Marcinski; V Barral; J Sauvegrain
Journal:  Pediatr Radiol       Date:  1985

2.  Lower extremity swelling: computerized tomography following negative venography.

Authors:  G Pillari; J Zito; J B Chang; J R Cohen; B Greenspan; K Gersten; P Wenig; B Lewin; A Rizzo
Journal:  Cardiovasc Intervent Radiol       Date:  1987       Impact factor: 2.740

3.  Emergency department investigation of deep vein thrombosis.

Authors:  D A Kilroy; S Ireland; P Reid; S Goodacre; F Morris
Journal:  Emerg Med J       Date:  2003-01       Impact factor: 2.740

4.  Clinical Risk Factors of Asymptomatic Deep Venous Thrombosis in Patients With Acute Stroke.

Authors:  Yi Wang; Yu Shi; Yi Dong; Qiang Dong; Ting Ye; Kun Fang
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.